Recent Analysts’ Ratings Updates for Neurocrine Biosciences (NBIX)
A number of research firms have changed their ratings and price targets for Neurocrine Biosciences (NASDAQ: NBIX): 12/23/2024 – Neurocrine Biosciences had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $160.00 price target on the stock. 12/23/2024 – Neurocrine Biosciences had its price target raised by analysts at Barclays PLC […]
More Stories
Pacific Investment Management Sells 228,195 Shares of Quantum Co. (NASDAQ:QMCO) Stock
Quantum Co. (NASDAQ:QMCO – Get Free Report) major shareholder Pacific Investment Management sold 228,195 shares of the stock in a...
Insider Selling: Sunrun Inc. (NASDAQ:RUN) CFO Sells 3,734 Shares of Stock
Sunrun Inc. (NASDAQ:RUN – Get Free Report) CFO Danny Abajian sold 3,734 shares of the business’s stock in a transaction...
Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells 11,337 Shares of Stock
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in...
Insider Selling: Lifeway Foods, Inc. (NASDAQ:LWAY) Major Shareholder Sells 45,000 Shares of Stock
Lifeway Foods, Inc. (NASDAQ:LWAY – Get Free Report) major shareholder Ludmila Smolyansky sold 45,000 shares of Lifeway Foods stock in...
Lattice Semiconductor Co. (NASDAQ:LSCC) SVP Mark Jon Nelson Sells 1,850 Shares
Lattice Semiconductor Co. (NASDAQ:LSCC – Get Free Report) SVP Mark Jon Nelson sold 1,850 shares of the company’s stock in...
Ferrexpo (LON:FXPO) Trading Down 7.9% – Should You Sell?
Ferrexpo plc (LON:FXPO – Get Free Report) was down 7.9% during mid-day trading on Tuesday . The company traded as...